SST and prostate adenocarcinoma: Since it isaccepted that the antiproliferative effect of somatostatin results from itsaction via the endocrine pathway, evidence also exists that somatostatin canalso act via an autocrine/paracrine pathway which has been recently describedin PC-3 and LNCaP cells, two human prostate adenocarcinoma cell lines [29].